NCT07359924

PRF in Face Care Cream.

Completed Phase 2 Last updated 22 January 2026

What this trial tests

Phase 2 trial testing The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 in Skin Ageing in 20 participants. Completed in 6 February 2023.

Timeline

3 February 2022

Primary endpoint
8 August 2022

6 February 2023

Quick facts

Lead sponsor	Poznan University of Medical Sciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	single
Primary purpose	prevention
Enrollment	20
Start date	3 February 2022
Primary completion	8 August 2022
Estimated completion	6 February 2023
Sites	1 location across Poland

Drugs / interventions tested

• The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20
• The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGF
• The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRF — full drug profile →

Conditions studied

• Skin Ageing — all drugs for Skin Ageing →

Sponsor

Poznan University of Medical Sciences

Who can join

Adults 20 to 40, female only, with Skin Ageing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates the effectiveness of cosmetic preparations containing PRF, conducted through in vivo studies. Material and Methods: The study involved 20 healthy volunteers (aged 20-40) who received three identically packaged creams to be applied to specific facial areas. Formulation 1: base formulation (control), Formulation 2: base formulation with human epidermal growth factor (EGF), and Formulation 3: base formulation with platelet-rich fibrin (PRF). Volunteers applied the creams as directed for a period of four weeks. Skin assessments was conducted at baseline (week 0), and at weeks 1, 2, and 4. Trans-epidermal Water Loss (TEWL), skin hydration using corneometry to determine the moisture content of the stratum corneum, skin elasticity using a cutometer to measure the skin's ability to return to its original state after deformation, and dermal bioavailability were measured. EGF concentration in the stratum corneum will be measured using the tape-stripping method followed by HPLC (High-Performance Liquid Chroma-tography) analysis. Results: A significant decrease in TEWL was observed in formulations 2 and 3, indicating improved skin barrier function. Formulation 3 showed the highest increase in skin hy-dration, followed by formulation 2. Both formulations 2 and 3 demonstrated improvements in skin elasticity, with formulation 3 showing the greatest enhancement. EGF concentration in the stratum corneum increased over the four-week period, reaching equilibrium with the product concentration by week four. Con-clusion: The in vivo instrumental compatibility studies confirmed that the new cosmetic formulations containing EGF and PRF are safe and effective for human skin.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Instrumental In Vivo Assessment of Cosmetic Emulsions Containing Platelet-Rich Fibrin (PRF) or Recombinant Epidermal Growth Factor (EGF): A Pilot Compatibility Study.
   Wyganowska ML, Tyliszczak F, Marzec M, Klewin-Steinböck S, et al · · 2026 · PMID 41901242 · DOI 10.3390/ph19030394